RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy In Greece


Article Opinions: 1 posts
RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce the opening of another state of the art facility in Greece for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

The Company's treatment for congestive heart failure is administered at the Metropolitan Hospital in Athens, which is part of the PERSEUS Heath Care Group. Greece is a convenient location for patients living in Europe and offers patients an additional location where the company's autologous stem cell treatments are permitted.

Cardiac Disease

There are therapies to treat congestive heart failure. But there comes a treatment point when the only option may be a heart transplant. Over 25,000 people are on the transplant lists but fewer than 2,500 receive one. The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.

Peripheral Artery Disease

The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.

Since 2005, the company's stem cell therapy has successfully treated over 500 patients. The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live. A half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel. There the patient's stem cells are extracted and grown from tens of thousands into many millions. The stem cells are primed for angiogenesis or blood vessel formation. The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catherization laboratory in a procedure similar to angioplasty.

Source: RegenoCELL Therapeutics, Inc


Stem Cell Treatment May Restore Cognitive Function In Patients With Brain Cancer



Stem cell therapy may restore cognition in patients with brain cancer who experience functional learning and memory loss often associated with radiation treatment, according to a laboratory study published in Cancer Research, a journal of the American Association for Cancer Research.

Charles Limoli, Ph.D., a professor in the department of radiation oncology at the University of California, Irvine, said radiation therapy is the standard of care for most brain cancers, but the side effects can be devastating.

"In almost every instance, people experience severe cognitive impairment that is progressive, debilitating and adversely impacts quality of life," he said. "Pediatric cancer patients can experience a drop of up to three IQ points per year."

In the current study, Limoli and colleagues subjected rats to cranial irradiation and followed up two days later with human neural stem cell transplants. A significant proportion of these cells survived and turned into brain cells found at one- and four-month evaluations. Cognitive function significantly improved compared with control rats.

Limoli said the findings of this study were significant, and may help pave the way for a human safety trial to be conducted within a few years if appropriate funding can be secured. Neural stem cells like those used in this study do not present the same ethical questions as embryonic stem cells.

Source: American Association for Cancer Research (AACR)


Clinical Trial Of New Stem Cell Therapy For Use In Patients Up To 19 Days After Stroke



The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston (UTHealth) in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

The Phase II study, cleared by the Federal Drug Administration, examines a regenerative therapy developed by Aldagen that uses a patient's own bone marrow stem cells. The therapy, called ALD-401, consists of stem cells that are identified using Aldagen's proprietary technology to isolate cells that express high levels of an enzyme that serve as a marker of stem cells. Studies found that these cells enhance recovery after stroke in mice. The cells are administered into the carotid artery.

"This represents a new approach using stem cells for stroke," said Sean Savitz, M.D., senior investigator for the multi-center study and associate professor of neurology at the UTHealth Medical School. "A major question in the field of stem cell research is whether we can extend the time window for administering stem cells. A longer window increases the number of patients that might be helped."

Preclinical research, including research at UTHealth, has suggested that stem cells can promote the repair of the brain after an ischemic stroke, which is caused by a blood clot in the brain. Stroke is a leading cause of disability and the fourth-leading cause of death in the United States, according to 2008 statistics reported by the Centers for Disease Control and Prevention.

The Houston resident (who cannot be identified by name at this time because of the study design) received either placebo or ALD-401 on June 8 at Memorial Hermann-Texas Medical Center after suffering a stroke May 23 while on a trip to California. Her stroke was caused by previously undiagnosed atrial fibrillation.

"We were waiting for our taxi at the hotel and I immediately couldn't talk and my husband said my face was drooping," said the 67-year-old cosmetics developer. "We were just three blocks from a major trauma center. I had an angel with me because if it had happened two hours later, I would have been on an airplane."

Once back in Houston, she was referred to Savitz' study by Erin Furr-Stimming, M.D., UTHealth assistant professor of neurology, who treats her for Parkinson's disease.

While she doesn't know whether or not she received the stem cells in the double-blind study, she didn't hesitate to join the trial.

"I did a lot of research on stem cells online. I was very excited when I heard about the trial. I wanted to participate in the research for me, if possible, and for other people behind me," she said.

Savitz and his research team are studying other stem cell therapies for acute stroke, and these must be administered within a few days of the stroke. One of those, a safety and efficacy trial using a patient's own bone marrow stem cells administered intravenously, is funded by the National Institutes of Health. UTHealth researchers in the Department of Pediatric Surgery also are studying the use of stem cells for pediatric traumatic brain injury.

Savitz' team is working to enroll patients at other area hospitals and facilities into the study, something that is possible because the cells can be administered up to 19 days after a stroke. The trial, funded by Aldagen, will enroll a total of 100 patients with unilateral (one-sided) cortical ischemic strokes. For information, call 713-500-7183 or email jennifer.m.garrett


 

Healthy Medicine Copyright © 2010 LKart Theme is Designed by Lasantha